S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

BTAI BioXcel Therapeutics Inc

2.54

0.00 (0.00%)

Pre Market

Last Updated: 05:33:56

Delayed by 15 minutes

Universe Pharmaceuticals, Applied Molecular Transport leads healthcare gainers; AzurRx BioPharma, BioXcel Therapeutics among ...

To read the full story on Seeking Alpha, click here.

BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more BioXcel Therapeutics Charts.

BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more BioXcel Therapeutics Charts.

BioXcel Therapeutics Inc News

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
Thursday 25 April 2024 (1 week ago) • GlobeNewswire Inc.

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
Wednesday 24 April 2024 (1 week ago) • GlobeNewswire Inc.

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
Monday 22 April 2024 (1 week ago) • GlobeNewswire Inc.

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
Wednesday 10 April 2024 (3 weeks ago) • GlobeNewswire Inc.

BioXcel Therapeutics Announces $25 Million Registered Direct Offering
Monday 25 March 2024 (1 month ago) • GlobeNewswire Inc.

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
Friday 15 March 2024 (2 months ago) • GlobeNewswire Inc.

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
Tuesday 12 March 2024 (2 months ago) • GlobeNewswire Inc.

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
Friday 1 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 14 February 2024 (3 months ago) • Edgar (US Regulatory)

BioXcel Therapeutics Announces Termination of Proposed Public Offering
Tuesday 13 February 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 12 February 2024 (3 months ago) • Edgar (US Regulatory)

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
Monday 12 February 2024 (3 months ago) • GlobeNewswire Inc.

More BioXcel Therapeutics Inc News Articles

Global Developments (PK)

Atacama Resources (PK)

FBEC Worldwide (PK)

Mullen Automotive

NaturalShrimp (QB)

NioCorp Developments

Federal Home Loan Mortgage (QB)

Branded Legacy (PK)

Moon Equity (PK)

MicroCloud Hologram

International Star (PK)

Fannie Mae (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions